Immunovaccine to Present at 2018 BIO CEO & Investor Conference
February 02 2018 - 7:05AM
Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage
immuno-oncology company, today announced it will participate in
this year’s BIO CEO and Investor Conference in New York, NY. This
event takes place February 12-13, 2018, at the New York Marriott
Marquis.
Frederic Ors, Immunovaccine’s Chief Executive Officer, is
scheduled to present a corporate overview and update on Tuesday,
February 13, at 9:15 AM ET in the Wilder Room. The presentation
will be available on Immunovaccine’s website at www.imvaccine.com
following the meeting.
The BIO CEO & Investor Conference is one of
the largest investor conferences focused on established and
emerging publicly traded, and select private, biotech
companies.
About Immunovaccine
Immunovaccine Inc. is a clinical-stage biopharmaceutical
company dedicated to making immunotherapy more effective, more
broadly applicable, and more widely available to people facing
cancer and infectious diseases. Immunovaccine is
developing T cell-activating cancer immunotherapies based on its
patented immuno-stimulating technology platform, which provides
controlled and prolonged delivery of immuno-stimulating agents to
the immune system.
Immunovaccine has advanced two T cell activation therapies
for cancer through Phase 1 human clinical trials, and is currently
conducting multiple Phase 1b and Phase 2 studies with Incyte
Corporation and Merck. These studies are assessing lead
candidate, DPX-Survivac, as a combination therapy in ovarian cancer
and diffuse large B cell lymphoma. The Company is also exploring
additional applications of its platform for infectious diseases and
other therapeutic areas. DPX-RSV is an innovative vaccine candidate
for respiratory syncytial virus (RSV), which has recently completed
a Phase 1 clinical trial. Connect at www.imvaccine.com.
Immunovaccine Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Company, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law.
Contacts for Immunovaccine:
MEDIA Mike Beyer, Sam Brown
Inc.T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONSPierre Labbé, Chief
Financial OfficerT: (902) 492-1819
E: info@imvaccine.com
Patti Bank, Managing Director, Westwicke
PartnersO: (415) 513-1284T: (415) 515-4572 E:
patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024